Company performance
Add to research
Current Price
as of Mar 12, 2025$33.60
P/E Ratio
13.36
Market Cap
$1.88B
- HRMY
Description
Add to research
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders. Its product, WAKIX, is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded by Jeffrey S. Aronin on July 25, 2017 and is headquartered in Plymouth Meeting, PA.
Metrics
Add to research
Overview
- HQPlymouth Meeting, PA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerHRMY
- Price$33.6-0.15%
Trading Information
- Market cap$1.88B
- Float75.82%
- Average Daily Volume (1m)780,649
- Average Daily Volume (3m)636,324
- EPS$2.56
Company
- Revenue$714.73M
- Rev growth (1yr)22.80%
- Net income$145.49M
- Gross margin74.72%
- EBITDA margin30.07%
- EBITDA$214.94M
- EV$1.76B
- EV/Revenue2.46
- P/E13.36
- P/S2.72
- P/B2.91
- Debt/Equity35.37
Documents
Add to research
SEC Filings
Earnings Calls
Factset Street Account